A Case of Comorbid Myxoma and Chronic Lymphocytic Leukemia: Not Just a Coincidence?

Author:

Laird-Fick Heather1,Tiwari Ashish1,Narayanan Santhosshi2,Qin Ying3,Vodnala Deepthi4,Bhutani Manisha5

Affiliation:

1. Department of Medicine, Michigan State University College of Human Medicine, 788 Service Road Suite B301, East Lansing, MI 48824, USA

2. Good Shepherd Medical Center, 700 East Marshall Avenue, Longview, TX 75601, USA

3. Pathology Department, EW Sparrow Hospital, 1215 East Michigan Avenue, Lansing, MI 48909-7980, USA

4. St. John Hospital and Medical Center, VEP, 2nd Floor, Cath Lab, Internal Mailbox 110, 22101 Moross Road, Detroit, MI 48236, USA

5. Center for Cancer Research, National Cancer Institute, Lymphoid Malignancies Branch, 10 Center Drive 10/12N226, Bethesda, MD 20892, USA

Abstract

Background. It is unclear why cardiac myxomas develop. We describe a case of comorbid myxoma and chronic lymphocytic leukemia (CLL) to offer insights into the tumor’s pathophysiology.Case. A 56-year-old female with recurrent venous thromboembolism developed embolic stroke. Transesophageal echocardiogram showed a 1.7 × 1 cm sessile left atrial mass at the interatrial septum. Histopathology revealed myxoma with a B cell lymphocytic infiltrate suggestive of a low grade lymphoproliferative disorder. Bone marrow biopsy and flow cytometry of blood and the cardiac infiltrate supported the diagnosis of atypical CLL. She was followed clinically in the absence of symptoms, organ infiltration, or cytopenia. After eighteen months, she developed cervical and axillary lymphadenopathy. Biopsy confirmed B cell CLL/small lymphocytic lymphoma. She elected to undergo chemotherapy with fludarabine, cyclophosphamide, and rituximab, with clinical remission.Conclusions. The coexistence of two neoplastic processes may be coincidental, but the cumulative likelihood is estimated at 0.002 per billion people per year. A shared pathogenic mechanism is more likely. Possibilities include chronic inflammation, vascular endothelial growth factor A, shared genetic mutations, changes in posttranslational regulation, or alterations in other cellular signaling pathways. Additional studies could expand our current understanding of the molecular biology of both myxomas and CLL.

Publisher

Hindawi Limited

Subject

Oncology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3